Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania.
OBJECTIVE
To determine the impact of deworming on anaemia as part of a large-scale school-based anthelmintic treatment programme in the Tanga Region of the United Republic of Tanzania.


METHODS
Both the reduction in the prevalence of anaemia and the cost per case prevented were taken into consideration. Cross-sectional studies involved parasitological examination and anaemia evaluation before and at 10 months and 15 months after schoolchildren were dewormed.


RESULTS
Baseline studies indicated that the prevalence of anaemia (haemoglobin < 110 g/l) was high (54%) among schoolchildren, particularly those with high intensities of hookworm and schistosomiasis. Attributable fraction analysis suggested that hookworm and schistosomiasis were responsible for 6% and 15% of anaemia cases, respectively. Fifteen months after deworming with albendazole and praziquantel the prevalence of anaemia was reduced by a quarter and that of moderate-to-severe anaemia (haemoglobin <90 g/l) was reduced by nearly a half. The delivery of these anthelmintics through the school system was achieved at the relatively low cost of US$ 1 per treated child. The cost per anaemia case prevented by deworming schoolchildren was in the range US$ 6-8, depending on the haemoglobin threshold used.


CONCLUSIONS
The results suggested that deworming programmes should be included in public health strategies for the control of anaemia in schoolchildren where there are high prevalences of hookworm and schistosomiasis.
Guyatt
H L
HL
Wellcome Trust Centre for the Epidemiology of Infectious Disease, Department of Zoology, University of Oxford, England. Hguyatt@wtnaorobi.mimcom.net
Brooker
S
S
Kihamia
C M
CM
Hall
A
A
Bundy
D A
DA
D015766:Albendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D000740:Anemia / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D006293:Health Promotion; D006725:Hookworm Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D011223:Praziquantel / Q000008:administration & dosage / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000150:complications / Q000188:drug therapy; D013636:Tanzania / Q000453:epidemiology; D016896:Treatment Outcome
D000871:Anthelmintics; D011223:Praziquantel; D015766:Albendazole